Autologous Peripheral Blood Stem Cell Transplantation for Systemic Lupus Erythematosus

胡通林,黄敏,欧冬梅,肖毅,黄伟,周剑峰,张东华,孙汉英,刘文励,胡绍先,张义成

DOI: https://doi.org/10.3969/j.issn.1009-881x.2008.01.025

2007-01-01

Abstract:Objective To investigate the clinical efficacy and safety of autologous peripheral blood stem cell transplantation(APBSCT)for refractory systemic lupus erythematosus(SLE).Methods Ten patients with refractory SLE received APBSCT.Peripheral blood stem cells were mobilized by cyclophosphamide(CTX) at 2～4 g/m~2 and granulocyte colony-stimulating factor(G-CSF)at 5～10μg·kg~(-1)·d~(-1).Pretreatment regimen was consisted of CTX(50 mg·kg~(-1)·d~(-1),-6～-3d)and anti-thymocyte globulin(ATG 15～20 mg·kg~(-1)·d~(-1),-2d、-1 d、1d、2d).Every patient was infused more than2×10~6/kg CD34~+ cells.The clinical presentation,SLE dis- ease activity index(SLEDAI)and immunological changes were assessed.Results The clinical manifestations of the 10 patients returned to remission.The SLEDAI score after APBSCT was low.Their hematopoietic recon- stitution was successful.The median time for granulocyte count to reach higher than0.5×10~9/L was 9.5 days, and was 11 days for platelet20×10~9/L.The proteinuria decreased or disappeared.The antinuclear antibody decreased or became negative.The level of complement was increased.The following complications were ob- served:septicemia in 2 patients,cytomegalovirus infection in 2 patients,renal toxicity in 1 patient,acute left heart failure in 3 patients and cardiac arrhythmia in 3 patients.There was no transplantation related mortality. Conclusion APBSCT may improve the disease activity and the immunological markers in SLE.It is a valid therapy for refractory SLE,but the long-term effects need to be observed.